Global Thalassemia Market - 2024-2031

Global Thalassemia Market - 2024-2031

Global Thalassemia Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing with a CAGR of XX % during the forecast period 2024-2031.

Thalassemia represents a substantial health burden, particularly in regions where the prevalence is high. Individuals with severe forms of thalassemia require lifelong medical care, including blood transfusions, iron chelation therapy, and management of complications such as organ damage and infections. Thalassemia is a genetic disorder that affects the production of hemoglobin, leading to anemia and potentially life-threatening complications.

Thalassemia disproportionately affects populations in low- and middle-income countries, where access to comprehensive healthcare services and specialized thalassemia treatment centers may be limited. Addressing thalassemia requires efforts to reduce health disparities and improve access to affordable, high-quality care for all individuals, regardless of their socioeconomic status or geographic location.

Market Dynamics: Drivers and Restraints

The high prevalence of thalassemia

The high prevalence of thalassemia plays a significant role in driving the thalassemia testing market. High prevalence often correlates with a higher incidence of thalassemia cases. Early diagnosis is essential for effective disease management and intervention. Thalassemia testing allows for the identification of affected individuals, enabling healthcare professionals to implement appropriate treatment plans and supportive care early in life.

For instance, according to Boston Children report stated that, about 300 million people around the world have the “thalassemia trait,” which puts them at risk of having children with some form of thalassemia. More than 1 million people have non-transfusion-dependent thalassemia, while more than 100,000 people have transfusion-dependent thalassemia. In the United States, there are at least 1,200 people with transfusion-dependent thalassemia.

Additionally, according to an article published in National Library of Medicine 2022, estimated that, the prevalence of β-thal trait in Central India ranged between 1.4 and 3.4%, while 0.94% β-TM was reported among the patients with anemia. Moreover, government initiatives aimed at raising awareness about thalassemia, implementing screening programs, and improving access to treatment contribute to market growth. Policies supporting reimbursement for thalassemia treatments also play a role.

Market Dynamics: Restraint

Adverse effects of treatment

Some treatments for thalassemia, such as iron chelation therapy, can have significant side effects, including gastrointestinal disturbances and organ toxicity. The potential for adverse effects may impact patient adherence to treatment regimens and could deter individuals from seeking or continuing treatment. Adverse effects of thalassemia treatments, such as iron chelation therapy, may lead to poor patient adherence to treatment regimens.

If patients experience significant side effects, they may be less likely to comply with their prescribed therapy, which can negatively impact their health outcomes and overall disease management. Patients may be reluctant to undergo treatments with known adverse effects, preferring to avoid potential risks even if it means foregoing necessary therapy. This can limit the uptake of certain treatments and reduce demand for products associated with adverse effects.

For more details of the report, Request for sample

Segment Analysis

The global thalassemia market is segmented based on disease type, treatment, end-user and region.

The alpha thalassemia from the Disease Type segment accounted for approximately 61.24% of share

The escalating prevalence of genetic disorders causing mutations in the HBA1 and HBA2 genes, which are crucial for the formation of alpha-globin chains, is primarily driving the alpha thalassemia segment. In addition to this, the inflating utilization of effective therapeutic interventions, including blood transfusions and iron chelation therapy, to manage disease symptoms, mitigate complications, and enhance the quality of life for patients, is also creating a positive outlook for the segment growth.

Moreover, the widespread adoption of supportive treatments, such as folic acid supplementation and regular monitoring of iron levels, that help to improve therapy outcomes in individuals suffering from alpha thalassemia is further rise of segment growth. Apart from this, the rising usage of advanced genetic testing and prenatal screening techniques in early diagnosis and risk assessment of the illness is acting as another significant growth-inducing factor.

These diagnostic approaches enable timely medical interventions and informed decision-making for expectant parents. Additionally, the emerging popularity of hematopoietic stem cell transplantation procedures, since they boost the production of healthy red blood cells within the body to eliminate the need for lifelong transfusions and reduce complications related to iron overload.

Geographical Analysis

North America accounted for approximately 41.04% of the market share in 2022

The rise of thalassemia in North America has been a significant health concern over the past few decades. Thalassemia is a genetic blood disorder characterized by abnormal hemoglobin production, leading to anemia and other complications. Regular blood transfusions are often required to manage the anemia associated with thalassemia major.

The demand for blood products has increased with the rising number of thalassemia patients. For instance, according to Blood Bank of Alaska, around 4.5 million Americans will need a blood transfusion each year. Approximately 29,000 units of red blood cells are needed every day in U.S. Additionally, Prolonged blood transfusions can lead to iron overload in thalassemia patients, requiring treatment with iron chelating agents.

The market for these therapies has expanded to meet the needs of the growing patient population. With increasing cultural diversity in North America, there has been a rise in interethnic marriages. Thalassemia is more prevalent in certain ethnic groups, and when carriers from these groups intermarry, there is a higher risk of their children inheriting the disorder.

COVID-19 Impact Analysis

During the pandemic, many healthcare resources were redirected to COVID-19 response efforts, leading to disruptions in routine healthcare services, including those for thalassemia patients. Non-urgent medical appointments, including regular blood transfusions and iron chelation therapy sessions, were postponed or canceled, affecting disease management for thalassemia patients. Blood shortages became a concern during the pandemic due to decreased blood donations resulting from social distancing measures, fear of contracting the virus, and restrictions on movement.

Thalassemia patients who require regular blood transfusions faced challenges in accessing the necessary blood supply, leading to potential complications from anemia. Thalassemia patients are considered vulnerable to COVID-19 due to their underlying health condition and the potential for complications from viral infections. This heightened vulnerability necessitated additional precautions, such as strict adherence to infection control measures, shielding or isolation, and vaccination prioritization for thalassemia patients.

Market Segmentation

By Disease Type
• Alpha
• Beta

By Treatment
• Iron Chelating Drugs
• Blood Transfusions
• Folic Acid Supplements
• Gene Therapy
• Others

By End-User
• Hospitals and Clinics
• Academic and Research Institutes
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Lonza Group Ltd, GlaxoSmithKline plc, Bluebird Bio Corporation, Novartis AG, CHIESI Farmaceutici S.p.A, Bellicum Pharmaceuticals, IONIS Pharmaceuticals, Kiadis Pharma, Bristol Myers Squibb, Vifor Pharma among others.

Key developments

 On January 3, 2024, Agios Pharmaceuticals, Inc, the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary endpoint of hemoglobin response. Statistical significance was also achieved for both key secondary endpoints associated with change from baseline in FACIT-Fatigue Score and hemoglobin concentration.

 In April 2021, Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics partnered to develop, manufacture and commercialize CTX001, an investigational CRISPR/Cas9-based gene editing therapy that is being developed as a potentially curative therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).

Why Purchase the Report??
• To visualize the global thalassemia market segmentation based on disease type, treatment, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of thalassemia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global thalassemia market report would provide approximately 69 tables, 58 figures and 187 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies